home / stock / ptscd / ptscd short
Short Information | Mosaic ImmunoEngineering Inc (OTCMKTS:PTSCD)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 26,168 |
Total Actual Volume | 72,099 |
Short Trends | |
---|---|
Cover Days | 9 |
Short Days | 3 |
No Change Days | 4 |
Averages | |
---|---|
Average Short Volume | 1,308 |
Average Short Percentage | 28.68% |
Is there a PTSCD Short Squeeze or Breakout about to happen?
See the PTSCD Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
12-30-2020 | $3.25 | $3.74 | $3.74 | $3.1 | 1,007 | 121 | 12.02% |
12-29-2020 | $3.25 | $3 | $3.25 | $3 | 1,865 | 223 | 11.96% |
12-28-2020 | $3.01 | $3.01 | $3.01 | $3.01 | 381 | 155 | 40.68% |
12-23-2020 | $4.15 | $3.94 | $4.6 | $3.23 | 1,861 | 875 | 47.02% |
12-21-2020 | $3.1 | $3.1 | $3.3 | $3.1 | 1,457 | 400 | 27.45% |
12-18-2020 | $3.1 | $3.6 | $3.6 | $3.1 | 673 | 15 | 2.23% |
12-17-2020 | $4 | $3.25 | $4 | $2.41 | 9,247 | 3,900 | 42.18% |
12-16-2020 | $3.3 | $3.3 | $3.3 | $3.3 | 1,539 | 1,238 | 80.44% |
12-15-2020 | $4.17 | $4.11 | $4.19 | $4.11 | 2,493 | 100 | 4.01% |
12-10-2020 | $3.04 | $3 | $4.43 | $3 | 6,168 | 1,475 | 23.91% |
12-09-2020 | $6.3 | $2.8 | $6.3 | $2.1 | 28,075 | 9,660 | 34.41% |
12-08-2020 | $6 | $7 | $7.5 | $6 | 5,887 | 3,250 | 55.21% |
12-07-2020 | $3.5 | $6 | $6.5 | $3.5 | 4,535 | 2,179 | 48.05% |
12-04-2020 | $2.55 | $2.95 | $2.95 | $2.275 | 1,100 | 277 | 25.18% |
12-03-2020 | $2.5 | $2.3 | $2.5 | $1.895 | 5,059 | 1,651 | 32.63% |
12-02-2020 | $2.5 | $2.5 | $2.5 | $2.5 | 752 | 649 | 86.3% |
News, Short Squeeze, Breakout and More Instantly...
Mosaic ImmunoEngineering Inc Company Name:
PTSCD Stock Symbol:
OTCMKTS Market:
NOVATO, CA / ACCESSWIRE / December 30, 2020 / Mosaic ImmunoEngineering Inc., (the "Company" or "Mosaic") (OTC PINK:PTSCD), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious dise...
-Preclinical Data Published in Peer Reviewed Journals Support Advancing the Program into Human Clinical Trials- -Company Plans to Initiate Discussions with Regulatory Agencies in Early 2021 to Review Its Strategy for IND or Equivalent Filing- -Data Generated in Companion Animals wi...